Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

Ähnliche Einträge

• Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX‐FP Prophylaxis in Hemophilia B: A Repeated Time‐to‐Event Analysis
  von: Sjoerd F. Koopman, et al.
  Veröffentlicht: (2025)
• Erratum to “Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX ‐ FP Prophylaxis in Hemophilia B: A Repeated Time‐to‐Event Analysis”
  Veröffentlicht: (2025)
• Concomitant Use of Oral Anticoagulants With Oral Dipeptidyl Peptidase‐4 Inhibitors and Serious Bleeding Events
  von: Thanh Phuong Pham Nguyen, et al.
  Veröffentlicht: (2024)
• Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A
  von: Nancy Wong, et al.
  Veröffentlicht: (2025)
• Impact of Age and Factor Xa Inhibitor Concentrations on Bleeding Risk in Patients with Atrial Fibrillation
  von: Shin‐Yi Lin, et al.
  Veröffentlicht: (2025)